---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036504"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:56:15.563817+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals appoints Ipek Erdogan-Trinkaus as CCO; cites Increlex closing and ET-400 launch

## Summary
- Ipek Erdogan-Trinkaus appointed Chief Commercial Officer, effective December 3, 2024.
- She previously served as GM of Pediatric Endocrinology at Tolmar, leading the FENSOLVI® launch.
- CEO Sean Brynjelsen highlights role at a critical time with Increlex closing in late-December and ET-400 launch in early 2025.
- Erdogan-Trinkaus brings rare disease commercial experience from Tolmar and other health/wellness companies.

## SEC filing metadata
- accession: 0001437749-24-036504
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924036504/0001437749-24-036504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924036504/eton20241127_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036504
- JSON: https://secwatch.observer/filing/0001437749-24-036504.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.